Clinical trials: Seborrheic Dermatitis
Seborrheic Dermatitis, Psoriasis of Scalp
Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp
Observational, descriptive, retrospective, multicenter study to evaluate the safety of the treatment with Sebryl® and / or Sebryl Plus® in the management of seborrheic dermatitis and psoriasis of the scalp in routine medical…
- Trial name
- NCT05105139
- Testing
- Allantoin/ Coal Tar/ Clioquinol, Allantoin/ Coal Tar/ Clioquinol/ Triclosan
- Where
- Mexico
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Psoriasis Vulgaris, Seborrheic Dermatitis
Comparison of Scalp Microbiota of the Psoriasis and Seborrheic Dermatitis Patients
A sterile swap specimen taken from the scalp of the patients with psoriasis vulgaris or seborrheic dermatitis and the volunteer control group will be examined in our study.
- Conditions
- Psoriasis Vulgaris, Seborrheic Dermatitis, Microbial Colonization
- Trial name
- NCT03807453
- Testing
- Microbiota
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Istanbul Medeniyet University
Seborrheic Dermatitis, Papulopustular Rosacea
PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea
This study is a double-blind, vehicle-controlled clinical trial. The study will take place at Icahn School of Medicine at Mount Sinai.
- Trial name
- NCT06013371
- Testing
- PF-07038124
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Severe Seborrheic Dermatitis
Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis
Seborrheic dermatitis is a chronic inflammatory dermatological disease, evolving by relapses, affecting mainly the face and scalp.
- Trial name
- Disease (NCT02004860)
- Testing
- Protopic (R), Mycoster (R)
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Rouen
Seborrheic Dermatitis
Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
This is an open-label, long-term safety study of roflumilast ARQ-154 foam 0.3% in subjects with seborrheic dermatitis involving up to 20% total Body Surface Area (BSA). Study was applied topically once daily for 52 weeks.
- Trial name
- NCT04445987
- Testing
- ARQ-154
- Where
- 39 sites in United States
- Volunteers
- 408 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Dermatitis, Melanoma (Skin Cancer)
Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care
This study aims to determine if an artificial intelligence (AI) medical device can help doctors more accurately identify a wide variety of skin conditions and improve the efficiency of patient consultations.
- Conditions
- Dermatitis, Melanoma (Skin Cancer), Alopecia, Urticaria
- Trial name
- LegitHealthSAN (NCT07428954)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 16 people
- Sponsor
- AI Labs Group S.L
HIV Infections, Primary Health Care
HIV Indicator Diseases in Hospital and Primary Care
Patients are frequently evaluated by physicians for medical work-up of HIV indicator conditions in hospital and in primary care at the general practitioner.
- Conditions
- HIV Infections, Primary Health Care, Acquired Immunodeficiency Syndrome, Sexually Transmitted Diseases, Viral
- Trial name
- #AwareHIV (NCT05225493)
- Testing
- Peer to peer feedback, HIV rapid test
- Where
- Netherlands
- Volunteers
- 1,500 people
- Sponsor
- Erasmus Medical Center
Seborrhoeic Eczema of the Scalp
K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp
Seborrhoeic eczema (SE) is a chronic, inflammatory skin disorder confined to areas of the head and trunk where sebaceous glands are most prominent.
- Trial name
- NCT01137331
- Testing
- K301
- Where
- 19 sites in Sweden
- Volunteers
- 201 people
- Sponsor
- Moberg Pharma AB
Seborrhoeic Dermatitis of the Scalp
Two Topical K40 Formulations in Adults With Seborrhoeic Dermatitis (SD) of the Scalp
Seborrhoeic dermatitis (SD) is a papulosquamous (presence of both papules and scales) disorder patterned on the sebum-rich areas of the scalp, face, and trunk. The current treatment does not cure the disease permanently.
- Trial name
- NCT01137630
- Testing
- K40a, K40b
- Where
- 11 sites in Sweden
- Volunteers
- 98 people
- Sponsor
- Moberg Pharma AB
Acne, Melasma
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
The study is conducted to determine if image-based computer grading can of acne, melasma, rosacea and seborrheic dermatitis correlate well to expert based clinical severity grading.
- Conditions
- Acne, Melasma, Rosacea, Seborrheic Dermatitis
- Trial name
- NCT05942248
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Integrative Skin Science and Research
Seborrheic Dermatitis
Evaluation of the Effectiveness of a Product Containing Topical Hydrocortisone in the Treatment of Seborrheic Dermatitis of the Face
Clinical single-blind randomized comparison with the overall objective of evaluating the clinical efficacy of the products Nutracort lotion and Nutracort cream in the treatment of seborrheic dermatitis on the face.
- Trial name
- 13244/2009 (NCT01024374)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Allergisa Pesquisa Dermato-Cosmetica LTDA
HIV, AIDS
HIV Indicator Diseases Survey Across Europe - UK Arm
In Europe many patients infected with HIV remain undiagnosed, although this percentage varies between 15-80% across the continent. In the UK it is estimated to be 27%.
- Conditions
- HIV, AIDS, Indicator Diseases/Indicator Conditions
- Trial name
- NCT01196468
- Testing
- HIV test (serological or salivary), Interview
- Where
- 2 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
Seborrheic Dermatitis
Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis
The purpose of this study is to determine whether proactive use of 0.1% tacrolimus ointment once or twice weekly can keep adult facial SD in remission and reduce the incidence of exacerbation.
- Trial name
- NCT01591070
- Testing
- Tacrolimus
- Where
- South Korea
- Volunteers
- 104 people
- Sponsor
- Pusan National University Hospital
Seborrhea, Seborrheic Dermatitis
Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea
Oral isotretinoin is the gold standard drug to treat moderate to severe acne. Other indications like seborrhea, seborrheic dermatitis have been suggested.
- Conditions
- Seborrhea, Seborrheic Dermatitis, Quality of Life
- Trial name
- NCT01139749
- Testing
- oral isotretinoin, salicylic acid and ciclopirox olamine
- Where
- Brazil
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Federal University of São Paulo
Cosmetic Management of Oily Scalp
Ozonated Oil Emulsion for Seborrhea in Women
This study evaluates a new ozonated oil-based hair cream for women with oily scalp (seborrhea). The cream contains natural oils (moringa, wheat germ, olive, and chili extract) treated with ozone, plus biotin (vitamin B7).
- Trial name
- OOSE (NCT07559617)
- Testing
- Ozonated oil-based cosmetic emulsion, Matched vehicle control
- Where
- Syria
- Volunteers
- 66 people
- Sponsor
- Chadi Khatib
Dermatitis, Seborrheic
STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%
Extina (ketoconazole) Foam, 2% was approved for marketing in the United States (US) in June 2007. Extina foam is indicated for topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older.
- Trial name
- NCT00703846
- Testing
- Ketoconazole
- Volunteers
- 498 people
- Sponsor
- Stiefel, a GSK Company
Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP)
Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists
This study aims to determine if an artificial intelligence (AI) medical device can help healthcare professionals more accurately diagnose rare and complex skin conditions.
- Conditions
- Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP), Eczema Atopic Dermatitis, Acute Generalized Exanthematous Pustulosis
- Trial name
- LegitHealth BI (NCT07428915)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- AI Labs Group S.L
Seborrheic Dermatitis
ZYG24002 Lotion to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Adult Patients With Mild to Moderate Seborrheic Dermatitis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase Ib clinical trial conducted in adult patients with mild to moderate seborrheic dermatitis (IGA-SD score of 2-3 points).
- Trial name
- NCT07404033
- Testing
- ZYG24002 0.5%, ZYG24002 0.75%, ZYG24002 1%
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Sinomune Pharmaceutical Co., Ltd
Seborrheic Dermatitis
Neurobiology of the Scalp in Seborrheic Dermatitis
Seborrheic dermatitis is a common, inflammatory skin condition that causes flaky, white to yellowish scales to form on oily areas such as the scalp or inside the ear.
- Trial name
- NCT02349854
- Testing
- Biopsy
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boston University
Dermatitis, Atopic, Dermatitis, Contact
Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis
Topical corticosteroids are largely used in dermatology. The major problem related to their use is that the same mechanisms underlying their therapeutic effects (antiinflammatory and antiproliferative) may lead to adverse events.
- Conditions
- Dermatitis, Atopic, Dermatitis, Contact, Dermatitis, Seborrheic, Psoriasis
- Trial name
- NCT01011621
- Testing
- 0.5% prednisolone acetate cream, 0.1% betamethasone valerate cream
- Volunteers
- 170 people
- Sponsor
- Mantecorp Industria Quimica e Farmaceutica Ltd.